# US 2022/0033888 A1 · Generating capture probes for spatial analysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033888 A1
- Document ID: US20220033888A1
- Status: Published application
- Kind: A1
- Application number: 17/312,247
- Filed: 2019-12-06
- Published: 2022-02-03
- Earliest claimed: 2018-12-10
- Assignees: 10x Genomics, Inc.
- Applicants: 10x Genomics, Inc.
- Inventors: Michael Schnall-Levin; Eswar Prasad Ramachandran Iyer; Yifeng Yin; Tarjei Sigurd Mikkelsen; Preyas Shah; Geoffrey McDermott; Adam Lowe; Joshua Delaney; Augusto Manuel Tentori; Rajiv Bharadwaj; Stefania Giacomello; Alexander Gagnon; Meghan L. F. Frey; Zachary Bent; Erik Leonard Henrik Borgstrom
- Web page: https://patentgrep.com/patent/US20220033888A1

## CPC

- C12Q 1/6844: Nucleic acid amplification reactions
- B01L 3/50853: {with covers or lids (closures for test tubes B01L3/50825)}
- B01L 3/545: {for laboratory containers}
- B01L 9/523: {for multisample carriers, e.g. used for microtitration plates}
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6841: In situ hybridisation
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- G01N 21/6458: {Fluorescence microscopy (fluorescence microscopes per se G02B21/0076 and G02B21/16)}
- G01N 33/4833: {of solid biological material, e.g. tissue samples, cell cultures (tissue in vivo A61B5/00; cell suspensions G01N33/48735)}
- G01N 35/00732: {Identification of carriers, materials or components in automatic analysers}
- G02B 21/16: adapted for ultraviolet illumination {; Fluorescence microscopes (G02B21/0076 takes precedence)}
- G02B 21/26: Stages; Adjusting means therefor
- G02B 21/34: Microscope slides, e.g. mounting specimens on microscope slides
- G02B 21/365: {Control or image processing arrangements for digital or video microscopes (G02B21/361, G02B21/362 take precedence)}
- B01L 2300/0829: Multi-well plates; Microtitration plates
- C12Q 1/6855: Ligating adaptors
- C12Q 1/6869: Methods for sequencing
- C12Q 2525/161: incorporating target specific and non-target specific sites
- C12Q 2525/179: incorporating arbitrary or random nucleotide sequences
- C12Q 2527/156: Permeability
- C12Q 2543/101: in situ amplification
- C12Q 2563/149: Particles, e.g. beads
- C12Q 2565/537: characterised by the capture oligonucleotide acting as a primer
- C12Q 2565/60: Detection means characterised by use of a special device
- C12Q 2600/158: Expression markers
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- G01N 2035/00752: {bar codes}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G02B: OPTICAL ELEMENTS, SYSTEMS OR APPARATUS

## Abstract

The present disclosure relates to compositions and methods for generating capture probes on a substrate for identifying the location of analytes in a biological sample.

## Claims

### Claim at position 1

1-253. (canceled)

### Claim 254

A method for generating a spatial array comprising:
(a) providing a substrate comprising a plurality of first oligonucleotides, wherein a first oligonucleotide of the plurality of first oligonucleotides is attached to a region of the substrate; and
(b) attaching a second oligonucleotide to an unattached end of the first oligonucleotide, wherein the second oligonucleotide comprises a spatial barcode.

### Claim 255 (depends on 254)

The method of claim 254, wherein the method further comprises after (b):
(c) attaching a third oligonucleotide to an unattached end of the second oligonucleotide.

### Claim 256 (depends on 254)

The method of claim 254, wherein the first oligonucleotide is attached to the substrate through its 5′-end and the second oligonucleotide is generated using spatially directed in situ synthesis on the 3′-end of the first oligonucleotide.

### Claim 257 (depends on 254)

The method of claim 254, wherein the second oligonucleotide has a length selected from 8 nucleotides, 9 nucleotides, 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides.

### Claim 258 (depends on 256)

The method of claim 256, wherein the in situ synthesis is light-directed synthesis.

### Claim 259 (depends on 254)

The method of claim 254, wherein two or more second oligonucleotides are attached to two or more first oligonucleotides, wherein a member of the two or more second oligonucleotides differs from another member of the two or more second oligonucleotides.

### Claim 260 (depends on 254)

The method of claim 254, wherein the first oligonucleotide and/or the second oligonucleotide comprises a protected phosphodiester and exocyclic amine moieties.

### Claim 261 (depends on 254)

The method of claim 254, wherein the substrate further comprises a substantially complementary oligonucleotide hybridized to the first oligonucleotide.

### Claim 262 (depends on 254)

The method of claim 254, wherein the first oligonucleotide has a length of at least about 2 nucleotides, 5 nucleotides, 8 nucleotides, 10 nucleotides, 15 nucleotides, 18 nucleotides, 20 nucleotides, 22 nucleotides, 25 nucleotides, 27 nucleotides, 30 nucleotides, 33 nucleotides, 35 nucleotides, or 40 nucleotides.

### Claim 263 (depends on 254)

The method of claim 254, wherein the first oligonucleotide is synthesized and subsequently attached to the substrate.

### Claim 264 (depends on 260)

The method of claim 260, wherein the phosphodiester and exocyclic amine moieties of the first oligonucleotide are protected prior to attachment of the first oligonucleotide to the substrate or the phosphodiester and exocyclic amine moieties of the first oligonucleotide are protected after attachment of the first oligonucleotide to the substrate.

### Claim 265 (depends on 254)

The method of claim 254, wherein the first oligonucleotide comprises a cleavage site.

### Claim 266 (depends on 254)

The method of claim 254, wherein the first oligonucleotide is attached to the substrate through a linker and wherein the linker comprises a chemical group comprising: silane, amine, peptide, polyethylene glycol, biotin, desthiobiotin, streptavidin, thiol, acrydite, azide, digoxigenin, hexynyl, or a combination thereof.

### Claim 267 (depends on 266)

The method of claim 266, wherein the linker is a branched linker or a dendrimeric linker.

### Claim 268 (depends on 255)

The method of claim 255, wherein the third oligonucleotide is attached to the second oligonucleotide by ligation.

### Claim 269 (depends on 268)

The method of claim 268, wherein any protected moieties of the first and second oligonucleotides are deprotected prior to ligating the third oligonucleotide to the second oligonucleotide.

### Claim 270 (depends on 255)

The method of claim 255, wherein the third oligonucleotide comprises a capture domain of at least 6 nucleotides in length at the 3′-end, wherein the capture domain comprises a poly-T sequence or a random sequence of 6 to 20 nucleotides in length.

### Claim 271

A method of generating a spatial array comprising:
(a) providing an array comprising a plurality of oligonucleotides, wherein the 3′ end of an oligonucleotide of the plurality of oligonucleotides is attached to a substrate;
(b) providing a plurality of primers, wherein a primer of the plurality of primers is substantially complementary to a portion of the oligonucleotide;
(c) extending the primer using the oligonucleotide as a template, thereby generating a first oligonucleotide with a free 3′ end
(d) extending the first oligonucleotide to produce a 3′ overhang;
(e) providing a splint oligonucleotide that hybridizes to the 3′ end of the first oligonucleotide; and
(f) ligating a second oligonucleotide to the 3′ end of the first oligonucleotide, wherein the second oligonucleotide comprises a sequence that is substantially complementary to a portion of the splint oligonucleotide, and wherein the second oligonucleotide comprises a capture domain, thereby generating a spatial array.

### Claim 272 (depends on 271)

The method of claim 271, wherein the oligonucleotide of the plurality of oligonucleotides comprises a spatial barcode, a first constant sequence, a second constant sequence, and combinations thereof.

### Claim 273 (depends on 272)

The method of claim 272, wherein the second oligonucleotide further comprises a unique molecular identifier, a spatial barcode, a constant sequence, wherein the constant sequence is substantially complementary to a portion of the splint oligonucleotide, and combinations thereof.

### Claim 274 (depends on 272)

The method of claim 272, wherein the capture domain comprises a poly(T) sequence or a gene-specific sequence.

### Claim 275 (depends on 271)

The method of claim 271, wherein the 3′ end overhang of step (d) is produced by a template-independent polymerase.

### Claim 276

A method of generating an array comprising:
(a) providing a substrate comprising a plurality of features immobilized on the substrate, wherein a feature of the plurality of features comprises a first oligonucleotide, and wherein the first oligonucleotide comprises a first spatial barcode;
(b) delivering a second oligonucleotide to the first oligonucleotide, wherein the second oligonucleotide comprises a second spatial barcode and a capture domain; and
(c) attaching the first oligonucleotide and the second oligonucleotide, thereby generating a capture probe comprising the first spatial barcode, the second spatial barcode, and the capture domain.

### Claim 277 (depends on 276)

The method of claim 276, wherein the first oligonucleotide comprises a unique molecular identifier and is associated with one of a number of different first spatial barcodes and the second oligonucleotide is associated with one of a number of different second spatial barcodes.

### Claim 278 (depends on 276)

The method of claim 276, wherein the attaching in step (c) comprises:
(i) ligating the first oligonucleotide and the second oligonucleotide, wherein the ligating comprises a ligase; or
(ii) the first oligonucleotide and the second oligonucleotide are attached by a chemical coupling reaction.

### Claim 279 (depends on 276)

The method of claim 276, wherein the first oligonucleotide comprises a 3′ end that is masked by a protective group, wherein the protective group is removed prior to delivering the second oligonucleotide to the first oligonucleotide.

### Claim 280 (depends on 279)

The method of claim 279, wherein the protective group is a photocleavable protective group, wherein the photocleavable protective group is protected by applying a photomask, and wherein the photocleavable protective group is removed by exposing the first oligonucleotide to light.

### Claim 281 (depends on 276)

The method of claim 276, wherein a first feature is separated from other features of the plurality by one or more physical barriers, wherein the one or more physical barriers comprise:
(i) a hydrophobic surface;
(ii) form one or more chambers, wherein the first oligonucleotide is delivered to a chamber of the one or more chambers; and
(iii) one or more chamber wall comprise a tapered end in contact with the substrate.
